Experiencia inicial del uso de SelectMDx® en el diagnóstico de cáncer de próstata en un entorno de práctica clínica habitual «real-world evidence»
Sign Up to like & getrecommendations! Published in 2020 at "Actas Urologicas Espanolas"
DOI: 10.1016/j.acuro.2020.03.005
Abstract: Resumen Introduccion El uso de biomarcadores en la deteccion del cancer de prostata (CP) puede disminuir el sobrediagnostico y sobretratamiento de CP no significativos. Analizamos la utilidad y aplicabilidad del marcador SelectMDx® en un entorno… read more here.
Keywords: riesgo; los; entorno; test ... See more keywords
Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study
Sign Up to like & getrecommendations! Published in 2018 at "Prostate Cancer and Prostatic Diseases"
DOI: 10.1038/s41391-018-0076-3
Abstract: BackgroundLow specificity of prostate-specific antigen results in a considerable number of unnecessary prostate biopsies in current practice. SelectMDx® predicts significant prostate cancer upon biopsy and is used to reduce the number of unnecessary initial prostate… read more here.
Keywords: prostate; cost; prostate cancer; cost effectiveness ... See more keywords